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of randomised controlled trials of rheumatoid arthritis
Jamie J Kirkham,1 Mike Clarke,2 Paula R Williamson1 
ABSTRACT
ObjeCtive
To assess the uptake of the rheumatoid arthritis core 
outcome set using a new assessment method of 
calculating uptake from data in clinical trial registry 
entries.
Design
Review of randomised trials.
setting
ClinicalTrials.gov.
subjeCts
273 randomised trials of drug interventions for the 
treatment of rheumatoid arthritis and registered in 
ClinicalTrials.gov between 2002 and 2016. Full 
publications were identified for completed studies 
from information in the trial registry or from an internet 
search using Google and the citation database Web of 
Science.
Main OutCOMe Measure
The percentage of trials reporting or planning to 
measure the rheumatoid arthritis core outcome set 
calculated from the information presented in the trial 
registry and compared with the percentage reporting 
the rheumatoid arthritis core outcome set in the 
resulting trial publications.
results
The full rheumatoid arthritis core outcome set was 
reported in 81% (116/143) of trials identified on the 
registry as completed (or terminated) for which results 
were found in either the published literature or the 
registry. For trials identified on the registry as 
completed (or terminated), using information only 
available in the registry gives an estimate for uptake of 
77% (145/189).
COnClusiOns
The uptake of the rheumatoid arthritis core outcome 
set in clinical trials has continued to increase over 
time. Using the information on outcomes listed for 
completed or terminated studies in a trial registry 
provides a reasonable estimate of the uptake of a core 
outcome set and is a more efficient and up-to-date 
approach than examining the outcomes in published 
trial reports. The method proposed may provide an 
efficient approach for an up-to-date assessment of the 
uptake of the 300 core outcome sets already 
published.
Introduction
The selection of appropriate outcomes is crucial to the 
design of randomised trials. If the findings of a trial are 
to influence healthcare, the outcomes that are mea-
sured and reported need to be relevant to patients, 
healthcare professionals, and others making decisions 
about healthcare provision. A core outcome set has 
previously been defined as an agreed standardised set 
of outcomes that should be measured and reported, as 
a minimum, in all clinical trials in specific areas of 
health or healthcare.1  Core outcome sets can enhance 
the relevance of research by ensuring outcomes of 
importance to health service users and other people 
making choices about healthcare in a particular set-
ting are measured routinely.2  The adoption of a core 
outcome set can reduce heterogeneity in reported out-
comes between trials and reduce the risk of outcome 
reporting bias, since trial reports would always include 
a presentation of the findings of a core outcome set, as 
a minimum.1
The OMERACT (Outcome Measures in Rheumatol-
ogy) Initiative advocates the use of a core outcome set 
and strives to improve outcome measures in musculo-
skeletal conditions through data driven multi-stake-
holder consensus processes.3  A brief history of 
OMERACT is provided elsewhere.4  After the first OMER-
ACT conference in 1992, the World Health Organization 
and International League of Associations for Rheuma-
tology (ILAR) ratified a core outcome set for clinical tri-
als of symptom modifying antirheumatic drugs in 
rheumatoid arthritis. The WHO-ILAR rheumatoid 
arthritis core outcome set was published in 1994 and 
consisted of seven outcomes (tender joints, swollen 
joints, pain, physician global assessment, patient 
global assessment, physical disability, and acute phase 
WhAT IS AlReAdy knoWn on ThIS TopIC
Core outcome sets can enhance the relevance of research by ensuring that a 
standardised set of outcomes are measured and reported in all trials for a specific 
clinical area
Assessing uptake allows the impact of development of core outcome sets to be 
evaluated, to improve implementation and ensure core outcome sets do not 
themselves contribute to waste in research by not being used
Previous methods used to estimate the uptake of core outcome sets have proved to 
be time consuming and inefficient
WhAT ThIS STudy AddS
The reporting of the rheumatoid arthritis core set of outcomes in completed trials 
was found to be 81%, corresponding to an uptake rate of 77% estimated from the 
information on outcomes listed in the trial registry
Reviewing outcomes listed in trial registries provides a reasonable estimate of the 
uptake of a core outcome set, and is less time consuming than examining the 
outcomes in published reports of trials
The method proposed provides an approach for assessing the uptake of the 300 
core outcome sets already published
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reactants), and one additional outcome (radiographs of 
the joints) for studies lasting one year or more.5
Assessing the uptake of a core outcome set allows the 
impact of research on the development of core outcome 
sets to be assessed. The uptake of the rheumatoid 
arthritis core outcome set has been previously assessed 
using a sample of 204 randomised trials of drug treat-
ments identified from those included in 31 Cochrane 
Reviews (published on the Cochrane Library up to Sep-
tember 2012 issue) of interventions for rheumatoid 
arthritis.6 These reviews included trials that were pub-
lished between 1955 and 2009. Over time there was an 
increase in the percentage of trials reporting the core 
outcome set items, with almost 70% measuring all 
these outcomes in trials that were published at the end 
of the first decade of the 21st century. However, assess-
ing the uptake of a core outcome set in this way can be 
a lengthy process because each individual trial report 
needs to be found and examined. Moreover, many sys-
tematic reviews can be several years old, meaning that 
the most up-to-date trials might not be included in the 
assessment.
We investigated the use of trial registries as a more 
efficient approach and up-to-date resource for assess-
ing the uptake of a core outcome set, using the rheuma-
toid arthritis core outcome set as our target example. We 
compared the uptake rates obtained by examining the 
trial registry entries with those obtained by checking 
the published reports of completed studies that had 
been registered in the registry, and examined whether 
the uptake of the rheumatoid arthritis core outcome set 
has improved since our previous study. With over 300 
core outcome sets already published for different health 
and healthcare settings,7  the new methodological 
uptake approach proposed in this research article has 
relevance for those from rheumatology and non-rheu-
matology communities to evaluate the uptake of core 
outcome sets in their area. Evaluation of uptake is cru-
cial to avoid core outcome sets being developed but 
never used, thus contributing to research waste,8 the 
very problem they are designed to tackle.
Methods
assessment of trial registry entries
We searched the trials registry ClinicalTrials.gov on 6 
October 2016 to identify all phase III/IV drug clinical 
trials of rheumatoid arthritis that had been registered 
on the site. To identify potentially relevant trials we 
applied the following filters: “conditions: rheumatoid 
arthritis”, “study type: interventional studies”, and 
“phase: 3 and 4”. The returned hits were exported into a 
spreadsheet and further filters were applied based on 
additional mandatory condition and study design fields 
recorded in the registry entries. We excluded trial regis-
try entries if the trial was not exclusive to participants 
with rheumatoid arthritis (eg, also contained partici-
pants with osteoarthritis), did not consider efficacy as 
an endpoint (eg, were safety studies, or pharmacoki-
netic, pharmacodynamic, or immunology studies only), 
considered a non-drug intervention or device, were 
non-randomised studies, were diagnostic test accuracy 
studies, or were studies where all participants received 
the same intervention (single group assignment). We 
applied these exclusions because these types of studies 
were beyond the scope of the current rheumatoid arthri-
tis core outcome set.
For each eligible trial registry entry, we extracted 
information on all planned trial outcomes and assessed 
whether the full rheumatoid arthritis core outcome set 
was listed. If trialists had registered a composite out-
come, such as the American College of Rheumatology 
improvement criteria,9 we considered all the individual 
outcomes in the composite in the assessment, even if 
they were not listed separately. For example, if the 
American College of Rheumatology 20 criteria were 
specified and the trial was less than 52 weeks in dura-
tion, then we assumed the full rheumatoid arthritis core 
outcome set was assessed.
assessment of trial reports
We searched for trial publications for all eligible trials 
that had been identified on the trial registry. We found 
relevant publications either directly from their listing in 
the trial registry entry, through a Google search for the 
clinical trial registry number (limited to the first three 
pages of Google hits), or through a search of the clinical 
trial registry number on a citation database, Web of Sci-
ence. Publications that included the clinical trial regis-
try number of a trial but did not report on the trial 
findings were excluded. An assessment of whether the 
full rheumatoid arthritis core outcome set was reported 
in each trial publication was carried out in the same 
way as for the trial registry entries. PRW checked a ran-
dom sample of 10% of the trial registry entries and pub-
lications, which showed agreement with another 
independent assessor (JJK). One reviewer (JJK), with 
experience in the assessment of the uptake of the rheu-
matoid arthritis core outcome set then carried out the 
remaining assessments.6
assessment of uptake of the rheumatoid arthritis 
core outcome set
Several measures of uptake were of interest, using data 
from either trial results, trial registry entries, or a com-
bination.
•	 The percentage of trials that reported data on the 
rheumatoid arthritis core outcome set for trials iden-
tified in the registry as completed (or terminated) 
where results were found either in a publication or in 
the trial registry. This is the gold standard approach 
and requires the most work to obtain the uptake esti-
mate, as all publications and trial results from the 
registry need to be found and read.
•	 The percentage of trials that reported or planned to 
measure data on the rheumatoid arthritis core out-
come set for trials identified in the registry with 
results found in the registry (either in a publication 
listed in the registry entry or in the trial registry). If 
the results were not found in the registry entry, the 
information on planned outcomes to be measured is 
taken from the trial registry entry. This method uses 
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only information from the registry and involves read-
ing the publications identified in the registry. It 
allows all eligible trials identified from the registry to 
be included in the evaluation of uptake.
•	 The percentage of trials that planned to measure data 
on the rheumatoid arthritis core outcome set for reg-
istered trials regardless of trial or publication status, 
based solely on the outcomes listed in the trial regis-
try entry. This method allows all eligible trials identi-
fied from the registry to be included in the evaluation 
of uptake regardless of whether they are ongoing or 
completed (or terminated) and does not require the 
reading of any publications.
•	 The percentage of trials that reported or planned to 
measure data on the rheumatoid arthritis core out-
come set for trials identified in the registry as com-
pleted (or terminated), based on the information in 
the trial registry. The aim of this approach is to esti-
mate uptake for completed (or terminated) trials 
using only the trial registry information and not from 
any wider search.
In our updated assessment of how the measurement of 
core outcomes had changed over time, we combined the 
data from the trial publications from the previous 
assessment (systematic review approach)6 with the data 
from the trial publications from this new assessment 
(trial registry entry approach). Any publications that 
were identified by both approaches contributed only 
once to the analyses. For the purposes of this assess-
ment, data from the trial registry entry approach were 
used for those studies with a trial publication only. If no 
publication was found but results had been included on 
the trial registry entry, we excluded these as this was an 
extra source of data that was not considered in the pre-
vious assessment. We ordered the published trials by 
publication date, divided them into blocks of 10, and 
calculated an average of the percentage reporting the 
full rheumatoid arthritis core outcome set over the pre-
vious 10 years. For example, the average for 2016 was 
taken to be the average percentage of trials reporting on 
the full rheumatoid arthritis core outcome set from 2007 
to 2016. Statistical analysis was carried out in Microsoft 
Excel 2010, and graphs were produced in R version 3.12.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in the dissemination of 
results.
Results
assessment of trial registry entries
After applying the relevant filters, a total of 652 rheuma-
toid arthritis trials were identified on ClinicalTrials.gov, 
with registration dates from 9 May 2002 to 17 August 
2016. After exporting the results and applying addi-
tional filters to meet the study inclusion criteria, 366 of 
the exported records were ineligible: 138 trials were not 
exclusive to rheumatoid arthritis, 35 did not consider 
efficacy as an endpoint, 17 did not consider a drug inter-
vention, and 176 did not use an eligible study design for 
this assessment (fig 1 ). After a review of the outcome 
Study ongoing, suspended, or withdrawn (n=84)Study completed or terminated (n=189)
Number of rheumatoid arthritis trials identied on ClinicalTrials.gov (n=652)
Number of phase III/IV rheumatoid arthritis ecacy trials with drug intervention (n=286)
Number of rheumatoid arthritis trials included in assessment (n=273)
No results
found (n=46)
Found using Google/
Web of Science (n=25)
Publication in trial
registry (n=97)
Results in trial
registry (n=21)
Uptake
Planned (30/46)
Uptake
Planned (17/25)
Results (18/25)
Uptake
Planned (76/97)
Results (83/97)
Uptake
Planned (16/21)
Results (15/21)
Uptake
Planned (45/84)
Exclusions (n=366):
  Not exclusive to rheumatoid arthritis (n=138)
  Non-ecacy study (n=35):
    Safety only (n=17)
    Pharmacokinetic/pharmacodynamic only (n=14)
    Immunology only (n=4)
  Non-drug intervention/device (n=17)
  Study design (n=176):
    Non-randomised (n=90)
    Single group assignment (n=85)
    Diagnostic test accuracy (n=1)
Exclusions based on trial registry entry data (n=13):
  Rheumatoid arthritis outcomes not well dened (n=12)
  Trials registry entry did not specify any outcomes (n=1)
Fig 1 | Flow diagram of rheumatoid arthritis trials registered on Clinicaltrials.gov and included in this study
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specifications within the registry entry, a further 13 
records were excluded: 12 owing to poor outcome spec-
ification (eg, remission was specified as an outcome, 
but the criteria for remission were not defined) and one 
entry did not specify any outcomes (entry registered in 
2002). This left 273 registry entries for this assessment 
(fig 1).
Of the 273 eligible registry entries, the recruitment 
status of 171 (63%) was shown as completed in Clinical-
Trials.gov while for the remaining 102 entries, recruit-
ment was either ongoing, not started, or the study was 
on hold or terminated prematurely (table 1 ). Similar 
percentages of trials planned to follow participants for 
less than six months (44%; 120/273) and for at least 12 
months (40%; 108/273). Most trials received commercial 
funding (table 1 ). About half the trials had a planned 
recruitment of between 100 and 500 participants (49%; 
134/273), and just over a third planned for more than 
500 participants (35%; 96/273). We found trial publica-
tions for nearly two thirds (65%; 122/189) of trials that 
were registered as completed (n=119) or terminated 
(n=3) (table 1 ). No trial publications were found for 
 trials that were ongoing, suspended, or withdrawn. 
Publications were listed on ClinicalTrials.gov for 97 tri-
als, and we found the remainder from our searches 
using Google and Web of Science. The median time 
from the trial start date (date that enrollment to the pro-
tocol began) recorded on the trial registry to the first 
recorded publication date (as recorded on the journal 
article) was about five years (table 1 ). Of the 67 trials 
registered as completed or terminated that had no trial 
publication, trial data were available on Clinicaltrials.
gov for 21, whereas no trial data were available for the 
remaining 46 trials (table 1).
Methods for assessing uptake of full rheumatoid 
arthritis core outcome set
The four uptake measures listed can be computed using 
the data presented in the bottom half of figure 1:
•	 The percentage reporting data on the full rheumatoid 
arthritis core outcome set was 81% (116/143) for trials 
identified on the registry as completed (or  terminated) 
when the trial results were found from any source.
•	 The percentage reporting or planning to measure 
data on the rheumatoid arthritis core outcome set 
was 70% (190/273) for trials where results were iden-
tified in the registry or where planned measurements 
were taken from the trial registry entry if results were 
not available.
•	 The percentage planning to measure data on the 
rheumatoid arthritis core outcome set was 67% 
(184/273) for registered trials regardless of trial or 
publication status, based on the outcomes listed in 
the trial registry entry.
•	 The percentage reporting or planning to measure 
data on the full rheumatoid arthritis core outcome set 
was 77% (145/189) for trials identified on the registry 
as completed (or terminated), where a publication or 
results were identified in the registry (ie, not from a 
wider search) or where planned measurements were 
taken from the trial registry entry if a publication or 
results were not available in the registry.
uptake of the rheumatoid arthritis core outcome set 
over time
The reporting of the full rheumatoid arthritis core out-
come set in trial publications over time is illustrated 
both for the previous approach of identifying trial pub-
lications from the inclusion of studies in systematic 
reviews (reported in6 ) and for the new approach of 
identifying trial publications from trial registry entries 
(fig 2 ). For 2006 to 2009, we found 20 trials that were 
published in the overlap period, 10 of which were 
included in the original evaluation and 10 of which 
were not included in our original evaluation. The origi-
nal approach based on systematic reviews found 10 tri-
als in the overlapping period, 8 (80%) of which reported 
the full core outcome set. The new method based on 
trial registry entries found 10 trials, 9 (90%) of which 
reported the full core outcome set. Figure 2 shows a 
table 1 | Characteristics and publication status of included rheumatoid arthritis trials 
registered on Clinicaltrials.gov
Characteristics
no (%) of 
trials (n=273)
Recruitment status:
 Completed 171 (63)
 Terminated 18 (7)
 Recruiting 44 (16)
 Enrolling by invitation 1 (<1)
 Suspended 4 (1)
 Not yet recruiting 34 (12)
 Withdrawn 1 (<1)
Trial duration (months):
 <6 120 (44)
 6-12 43 (16)
 ≥12 108 (40)
 Not specified 2 (<1)
Funding:
 Commercial 208 (76)
 Non-commercial 51 (19)
 Both 14 (5)
Planned sample size:
 <100 43 (16)
 100-500 134 (49)
 >500 96 (35)
Primary trial publication status (n=189)†:
 Trial published 122 (65)
  Publication listed on ClinicalTrials.gov 97
  Search for Clinical Trial Registry number using Google/Web of Science 25
 No trial publication found but trial data published on ClinicalTrials.gov 21 (11)
  Recruitment completed (results posted on ClinicalTrials.gov) 14
  Study terminated (results posted on ClinicalTrials.gov) 7
 No trial publication found (no trial data found) 46 (24)
  Recruitment completed (no results available) 38
  Study terminated (no results available) 8
Time to publication (n=122)‡:
 Median (interquartile range) number of years 4 (3-5)
 Median (interquartile range) number of days 354 (142-263)
*Recorded on ClinicalTrials.gov (6 October 2016).
†Recruitment status listed as either completed or terminated on ClinicalTrials.gov.
‡Taken from start date (date that enrollment to the protocol began, as recorded on ClinicalTrials.gov) to first 
recorded publication date (as recorded in the published article).
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 continuation over time in the upward trend in the 
 percentage of trials measuring the full rheumatoid 
arthritis core outcome set.
discussion
This study has shown that the uptake of the rheumatoid 
arthritis core outcome set, which was published in 
1994, has continued to increase over time. The increase 
in uptake was encouraging but the slighter increase in 
recent years perhaps suggests that further advances 
might be challenging, especially as some trialists do not 
measure the full rheumatoid arthritis core outcome set 
even though they are aware of its existence.6  In the pre-
vious assessment of the rheumatoid arthritis core out-
come set,6  we noted that the introduction of regulatory 
guidance—for example, from the Food and Drug 
Administration 1996,10  and European Medicines 
Agency 199811 —which were involved in ratifying and 
recommending the rheumatoid arthritis core outcome 
set, might have contributed to trials measuring these 
core outcomes. Uptake of the core outcome set  also 
increased before the publication of the core outcome set 
(1994), which perhaps indicates that consensus may 
have been developing; this was formalised by publica-
tion. Over 80% of the trials in this updated assessment 
received some commercial funding and therefore their 
adherence to the EMA/FDA guidance in general may 
have resulted in trialists using the rheumatoid arthritis 
core outcome set. In 2007 a patient perspectives work-
shop at OMERACT 8 (Outcome Measures in Rheumatol-
ogy) identified that fatigue was an important patient 
outcome for rheumatoid arthritis,12  as well as generic 
quality of life.13 Although this is an OMERACT recom-
mendation, no update of the core set has yet been rati-
fied. We found that 30 of the 203 trials received on the 
trial registry from 1 January 2008 planned to measure 
fatigue and 29 planned to measure quality of life, with 
16 planning to measure both.
A review of the outcomes listed in the trial registry 
entries suggested that the uptake of the rheumatoid 
arthritis core outcome set across all trials would be 
67%. Considering only those trials recorded as 
 completed or terminated, the uptake rate based on trial 
 registry information alone was 77%; this compared 
favourably to the uptake rate of 81% found through an 
assessment of trial results and publications. We suspect 
that the lower uptake statistic based on the trial registry 
entry data compared with that which combines infor-
mation from the registry entries and publications is 
largely a result of the quality of information recorded 
within a trial registry.14 15  For example, only a single 
 primary outcome was registered in four of the 12 trials 
where the full rheumatoid arthritis core outcome set 
was mentioned in the trial report. The information in a 
trial registry entry may also be subject to legitimate 
changes while a trial is ongoing, which means that 
uptake rates based on the registry entry for ongoing 
studies may be different from that for trials that are 
completed and published. Moreover, discrepancies in 
reported outcomes (in a trial report) that are not pre-
specified (in a trial registry) have previously been found 
to be common.16  Despite this difference in the number 
of trial registry entries listing the full rheumatoid arthri-
tis core outcome set and the number of trial publica-
tions doing so, we found that the use of trial registry 
entries to assess uptake of a core outcome set was effi-
cient and provides a more up-to-date method than 
identifying trials because of their inclusion in system-
atic reviews. It is also preferable to citation analysis, 
which is the only other method we have identified as 
having been used to assess the uptake of a core out-
come set.17  That approach was also applied to the rheu-
matoid arthritis core outcome set, but it proved 
unreliable because few of the reports of the trials 
that measured the core outcome set cited the relevant 
publication.17
strengths and limitations of this study
The strength of this study is that we considered all rheu-
matoid arthritis trials registered on ClinicalTrials.gov, 
which is one of the largest clinical study registries. 
While we acknowledge that more trials could have been 
identified if more primary registries were searched, 
such as all those registered with the World Health Orga-
nization International Clinical Trials Registry Platform 
(ICTRP), the trials identified on ClinicalTrials.gov are 
likely to be a representative sample of all trials that are 
registered in rheumatoid arthritis, given that trials 
entered onto the site are registered from across the 
world.18  Furthermore, since the International Commit-
tee of Medical Journal Editors (ICMJE) accepts registra-
tion in any registry that is a primary register of ICTRP or 
in ClinicalTrials.gov (a data provider for ICTRP), we do 
not anticipate that the trials registered in ClinicalTrials.
gov will differ in quality given that all trial registries 
endorsed by ICMJE must meet the same criteria.19 One 
potential difference between a sample drawn from Clin-
icalTrials.gov and from other registries is that the per-
centage of commercially funded trials on this US based 
registry might be higher, which could lead to higher 
estimates of uptake of core outcome sets if such trials 
are more likely to use the core outcome set for regula-
tory reasons. With regard to practicalities when 
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 considering ways to assess the uptake of a core outcome 
set, we found that ClinicalTrials.gov had a user friendly 
interface, which helped make this an efficient source of 
the outcomes measured in studies. With this in mind, 
we suggest that similar assessments should be carried 
out for core outcome sets from other treatment areas 
and that our work provides a template for an efficient 
method to conduct such assessments.
A potential limitation of this study is that one 
reviewer (JJK) carried out most of the assessments. 
However, a second author (PRW) independently 
checked a sample of registry entries and reports, and no 
discrepancies were identified. When considering the 
outcomes reported in trial publications, we also relied 
heavily on trial authors listing their publications in 
their trial entry on Clinicaltrials.gov. Although we sup-
plemented this with internet searches using Google and 
a citation database, we are likely to have missed some 
trial reports. The identification of the outcomes that are 
actually measured and reported in trials (as included in 
reports or datasets) compared with those that are 
planned to be measured (as included in registry entries) 
should become easier in the future—for example, as a 
result of US legislation (effective on Clinicaltrial.gov 
from January 2017), mandating the uploading of sum-
mary trial results within a certain time frame, indepen-
dent of decisions made about journal publication.20 
Improvements in automatic data linkage between pub-
lished articles and trial registry entries will also improve 
the process. One final notable limitation that may affect 
the estimate of uptake based on the method proposed is 
that trials would not be identified if they are not regis-
tered. The uptake rate of 81% calculated from reported 
data from trials that were identified as completed on the 
trial registry can be taken as our ideal method (with the 
caveat that unregistered trials might be less likely to 
measure the core outcome set). If trials that are not reg-
istered are of lower quality in general and less likely to 
be aware of the core outcome set and the importance of 
using it, our “gold standard” result for reported uptake 
might be an overestimate when compared with all trials 
undertaken.
relation to other studies and implications
In the broader context, a recently updated systematic 
review identified around 300 published and nearly 150 
ongoing core outcome sets,7  and therefore the present 
report provides evidence to support the potential 
value of core outcome sets for improving the quality of 
research and reducing waste. The current report high-
lights the successful implementation of a well estab-
lished core outcome set in rheumatoid arthritis. 
Although it appears to have taken over 20 years to 
reach a stable uptake rate for this particular core out-
come set, the promotion of core outcome sets by the 
COMET (Core Outcome Measures in Effectiveness Tri-
als).21  Initiative, and its referencing in guidelines for 
trialists,22  by funders,23  and from regulatory authori-
ties24  should accelerate uptake in the future. Further-
more, greater awareness of the need to consider the 
use of a core outcome set and inclusion of links to the 
core outcome set in registry entries25  should also have 
a positive impact, bearing in mind that many of the 
queries received by trial registry providers relate to the 
outcomes section.26
Conclusions
The adoption of a core outcome set has the potential to 
increase consistency in outcomes measured across tri-
als and ensure that trials are more likely to measure 
appropriate outcomes. The WHO-ILAR core outcome set 
for rheumatoid arthritis was first ratified in 1994, and 
recent trends suggest that there is a consistent increase 
in published trials of rheumatoid arthritis measuring it. 
This is the first study to assess the measurement of a 
core outcome set using trial registry information, which 
found that this was a more efficient and up-to-date 
approach than retrieving and assessing trial publica-
tions, and more reliable than citation analysis. The 
uptake rate estimated from trial registry information, 
which avoids the need to find and read trial publica-
tions that are not listed in the registry, seems to be rea-
sonably reliable when based on those trials recorded as 
completed or terminated in the registry. Our recom-
mended method for assessing uptake is therefore to 
identify trials in the relevant area of healthcare in the 
registry, select those that are completed or terminated, 
and then use the registry information (publication, 
results, or planned outcomes) to assess uptake of the 
core outcome set.
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